Infertility Clinical Trial
Official title:
Evaluation the Effect of Intrauterine Injection of Human Chorionic Gonadotropin Injection (hCG) Before Frozen Embryo Transfer on Implantation, Clinical Pregnancy and Miscarriage Rates: Double Blind Randomized Clinical Trial ,Phase 3
The present study is designed as a pilot study with 150 patients in each group. Data collection form will be filled by the researcher who does not know the type of intervention in each group. Data analysis will be done through descriptive and perceptive statistical methods by using SPSS software version 20 for windows
This randomized double blinded clinical trial is conducted to evaluate the effect of
intrauterine injection of human chorionic gonadotropin (hCG) before frozen embryo transfer
(ET). The study protocol is approved by the Ethics Committee (Institutional Review Board) of
Royan institute. The study is performed according to the Declaration of Helsinki for medical
research. All participants provide informed consent after explaining the purpose of the
study. All the patients with primary infertility who have only one fresh implantation failure
and undergoing frozen embryo transfer cycles are enrolled. In all patients, endometrial
preparation is performed by hormonal replacement method. In this way, endometrial preparation
is started from the second or third day of menstrual cycle with daily administration of 6 mg
oral estradiol valerate (Estraval®, Aburaihan CO, Tehran, Iran) for 8 days. After 8 days of
estradiol administration, if favourable thickness of endometrium (≥ 8 mm) is confirmed by
ultrasound, estradiol valerate is continued with the same dose and 50 mg progesterone
(Progestin®, Aburaihan Pharmaceutical. Co., Tehran, Iran) intramuscularly is administered for
3 days and then embryos are transferred. Otherwise the dosage of estradiol is increased to 8
mg/day until the favourable thickness of endometrium be achieved. In the Embryo transfer day,
the eligible patients are randomized using sealed opaque envelopes into three groups. In all
study groups, the patient is put in the lithotomy position, and the cervix is visualized
using Cusco's speculum. The cervical mucous is wiped out using a sterile piece of gauze, and
then the mucous is partially removed by gentle suction with a 1-mL syringe. Embryo transfer
is performed using a soft catheter (Labotec, Gottingen Germany). After the catheter is passed
the internal cervical os; in group A (experimental group) 40 μL of tissue culture medium
(G.2plus ref. 10132, Vitrolife) containing either 500 IU of hCG (Choriomon®, IBSA SA,
Switzerland) is injected intrauterine. In group B (the placebo group) only 40 μL of tissue
culture medium (G.2plus ref. 10132, Vitrolife) is injected intrauterine. In both groups,
approximately 7 minutes after injection, the embryos are loaded into another ET catheter and
are transferred into the uterine cavity. In group C (the control group), the ET is done
without the intrauterine hCG injection. The ET procedure is performed just like in the other
two groups.
According to the patients' age, up to 3 frozen-thawed Embryos are thawed and transferred at
cleavage stage. Hormone therapy is continued until pregnancy test (2 weeks after ET) is
performed and in case of positive pregnancy, administration of estradiol valerate and
progesterone continued by 10 and 12 weeks of gestation. Chemical pregnancy is defined by a
rising hCG level in serum without the detection of a gestational sac. Clinical pregnancy is
diagnosed by the presence of a gestational sac with fetal heart in vaginal ultrasonography.
The miscarriage rate is defined as the loss of pregnancy before 20 weeks' gestational age.
;
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT03607409 -
Role of Inhibin A as Biomarker for Ovarian Response for IVF Treatment
|
||
Recruiting |
NCT02312076 -
GnRHa for Luteal Phase Support in Long GnRHa Protocol Cycles
|
Phase 4 | |
Terminated |
NCT02161861 -
Improvement of IVF Fertilization Rates, by the Cyclic Tripeptide FEE - Prospective Randomized Study
|
N/A | |
Completed |
NCT03287479 -
Comparison of a Semi-automated Closed Vitrification System (Gavi®) With a Manual Open Vitrification Sytem (Cryotop®)
|
N/A | |
Terminated |
NCT03522350 -
Randomized Trial Comparing EmbryoScope With EmbryoScope+.
|
N/A | |
Completed |
NCT04496284 -
Embryo Transfer Outcomes After Vitrification With Slush Nitrogen Compared to Liquid Nitrogen
|
N/A | |
Completed |
NCT03623659 -
pArtiaL zonA pelluciDa Removal by assisteD hatchINg of Blastocysts
|
N/A | |
Completed |
NCT03895099 -
New Ovarian Stimulation With Random Start, Use of Progestin Protocol for Oocyte Donors
|
Phase 3 | |
Active, not recruiting |
NCT04142112 -
Randomized, Standard-Controlled, Study to Evaluate the Ohana IVF Sperm Preparation Kit, SPeRtility IVF Next Generation
|
N/A | |
Completed |
NCT03152643 -
Cumulative Live Birth Rates After Cleavage-stage Versus Blastocyst-stage Embryo Transfer
|
N/A | |
Recruiting |
NCT03683771 -
Assessment of Endometrial Pattern and Sub-endometrial Vascularity in ICSI Outcome
|
||
Recruiting |
NCT03161119 -
Comparing Two Different Embryo Transfer Catheters
|
N/A | |
Completed |
NCT04108039 -
Micronized Progesterone vs Gonadotropin-releasing Hormone (GnRH) Antagonist in Freeze-all IVF Cycles.
|
N/A | |
Completed |
NCT03678571 -
Oocyte Vitrification Aided With Latrunculin A
|
N/A | |
Completed |
NCT03678610 -
Handling Medium for ICSI With Ionomycin and Latrunculin A
|
N/A | |
Completed |
NCT03678584 -
Supplementing Intracytoplasmic Sperm Injection Handling Medium With Chaetoglobosin A ( ICSI-CA)
|
N/A | |
Completed |
NCT03678597 -
Supplementing Intracytoplasmic Sperm Injection Handling Medium With Latrunculin B ( ICSI-LB)
|
N/A | |
Completed |
NCT03678818 -
Supplementing Intracytoplasmic Sperm Injection Handling Medium With Latrunculin A (ICSI-LA)
|
N/A | |
Completed |
NCT03677492 -
Supplementing Intracytoplasmic Sperm Injection Handling Medium With Cytochalasin D ( ICSI-CD)
|
N/A | |
Completed |
NCT03678558 -
Oocyte Vitrification Aided With Cytochalasin B
|
N/A |